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Abstract: The aim of this study was to assess the combined use of the radiotracers 18F-FDG
and 18F-NaF in treatment response evaluation of a group of multiple myeloma (MM)
patients undergoing high-dose chemotherapy (HDT) followed by autologous stem cell
transplantation (ASCT) by means of static (whole-body) and dynamic PET/CT
(dPET/CT). Patients and methods: 34 patients with primary, previously untreated MM
scheduled for treatment with HDT followed by ASCT were enrolled in the study. All
patients underwent PET/CT scanning with 18F-FDG and 18F-NaF before and after
therapy. Treatment response by means of PET/CT was assessed according to the
European Organization for Research and Treatment of Cancer (EORTC) 1999 criteria.
The evaluation of dPET/CT studies was based on qualitative evaluation, semi-
quantitative (SUV) calculation, and quantitative analysis based on 2-tissue
compartment modelling and a non-compartmental approach leading to the extraction of
fractal dimension (FD).  Results: An analysis was possible in 29 patients: 3 with clinical
complete response (CR) and 26 with non-CR (13 patients near complete response-
nCR, 4 patients very good partial response-VGPR, 9 patients partial response-PR).
After treatment, 18F-FDG PET/CT was negative in 14/29 patients and positive in 15/29
patients, showing a sensitivity of 57.5% and a specificity of 100%. According to the
EORTC 1999 criteria, 18F-FDG PET/CT-based treatment response revealed CR in 14
patients (18F-FDG PET/CT CR), PR in 11 patients (18F-FDG PET/CT PR) and
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
95
33
8 
| 
do
wn
lo
ad
ed
: 
6.
1.
20
20
progressive disease in 4 patients (18F-FDG PET/CT PD). In terms of 18F-NaF
PET/CT, 4/29 pts (13.8%) had a negative baseline scan, thus failed to depict MM.
Regarding the patients, for which a direct lesion-to-lesion comparison was feasible,
18F-NaF PET/CT depicted 56 of the 129 18F-FDG positive lesions (43%). Follow-up
18F-NaF PET/CT showed persistence of 81.5% of the baseline 18F-NaF positive MM
lesions after treatment, despite the fact that 64.7% of them had turned to 18F-FDG
negative. Treatment response according to 18F-NaF PET/CT revealed CR in 1 patient
(18F-NaF PET/CT CR), PR in 5 patients (18F-NaF PET/CT PR), SD in 12 patients
(18F-NaF PET/CT SD), and PD in 7 patients (18F-NaF PET/CT PD). Dynamic 18F-
FDG and 18F-NaF PET/CT studies showed that SUVaverage, SUVmax, as well as the
kinetic parameters K1, influx and FD from reference bone marrow and skeleton
responded to therapy with a significant decrease (p<0.001). Conclusion: 18F-FDG
PET/CT demonstrated a sensitivity of 57.7% and a specificity of 100% in treatment
response evaluation of MM. Despite its limited sensitivity, the performance of 18F-FDG
PET/CT was satisfactory, given that 6/9 false negative patients in follow-up scans
(66.7%) were clinically characterized as nCR, a disease stage with very low tumor
mass. On the other hand, 18F-NaF PET/CT does not seem to add significantly to 18F-
FDG PET/CT in treatment response evaluation of MM patients undergoing HDT and
ASCT, at least shortly after therapy.
Response to Reviewers:
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 Dear Editor, 
 
Please find below our response to the Reviewers’ comments on our manuscript entitled 
“Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in 
multiple myeloma patients undergoing high-dose chemotherapy and autologous stem 
cell transplantation” 
by C. Sachpekidis, J. Hillengass, H. Goldschmidt, B. Wagner, U. Haberkorn,  
K. Kopka, A. Dimitrakopoulou-Strauss 
 
Reviewer #1:  
Adequate. No remarks 
 
 
Reviewer #2:  
Authors have made extensive modification on the original manuscript based on our 
comment. But two questions still remain to be answered.  
1. Authors provided the results of PFS and OS in the revised manuscript in Table 1. 
Data without appropriate analysis doesn’t lead to convincing conclusions. Authors 
did not proceed to survival analysis due to lack of late follow-up data for all 
patients. Why don't authors proceed to progression-free survival analysis? 
Authors’ response: We proceeded to progression-free survival analysis for 28 
patients, since, as already mentioned, one patient was lost to follow-up. By the 
time of writing 12 patients demonstrated progression. We dichotomized patients in 
PET/CT-positive (complete response) and PET/CT-negative (non-complete 
response) after therapy (follow-up scan). 6/12 patients demonstrated complete 
18F-FDG response and 6/12 patients had non-complete 18F-FDG response. The 
results of Kaplan-Meier analysis and a graph are now presented in the Point to 
point discussion (please see below Table 1, Figure 1). No statistically significant 
difference in PFS was observed between the 18F-FDG-positive and 
18F-FDG-negative patients. We would prefer not to include the results of this 
Authors' Response to Reviewers' Comments Click here to download Authors' Response to Reviewers'
Comments Point to point discussion 2.docx
analysis in the manuscript, since the number of events is still small. However, if 
the Reviewer insists, we could present them data as supplementary data. 
Due to the fact that only one patient showed complete response in 18F-NaF 
PET/CT (18F-NaF negative follow-up PET/CT), we did not perform similar 
dichotomization and survival analysis for this tracer. 
 
 
 
 Median (months) Mean (months) 
follow-up 18F-FDG negative  29.4 34 
follow-up 18F-FDG positive 39 30 
Table 1. Mean and median PFS values of the 12 patients demonstrating 
progression, dichotomized according to the result of follow-up 18F-FDG PET/CT. 
The PFS difference between these two groups was not statistically significant 
(log-rank p=0.848). 
 
  
Figure 1: Kaplan-Meier plot of PFS. No statistically significant difference in 
PFS between patients with negative (blue curve) and positive (green curve) 
follow-up 18F-FDG PET/CT (log-rank p = 0.848).  
 
 
2. I just want to know how to calculate the dosages of 18F-FDG and 18F-NaF. Table 
2 is unnecessary. The dosages can be described with interval numbers. 
Authors’ response: Table 2 was removed and dosage ranges of both tracers are 
now provided in text (pg 5, para 2, ln 6-7). There was a maximum limit of 250 
MBq for each PET exam, as defined by the federal radiation protection agency. 
The administered dose was not weight-dependent. We tried to apply as much 
activity as possible with respect to the predefined upper limit. Nevertheless, due to 
technical reasons (e.g. delays in delivery of tracer), in very few cases relative low 
doses of tracer activity were administered (for example baseline 18F-FDG PET/CT 
of patient 13). 
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ABSTRACT 
The aim of this study was to assess the combined use of the radiotracers 18F-FDG and 
18F-NaF in treatment response evaluation of a group of multiple myeloma (MM) 
patients undergoing high-dose chemotherapy (HDT) followed by autologous stem cell 
transplantation (ASCT) by means of static (whole-body) and dynamic PET/CT 
(dPET/CT). Patients and methods: 34 patients with primary, previously untreated 
MM scheduled for treatment with HDT followed by ASCT were enrolled in the study. 
All patients underwent PET/CT scanning with 18F-FDG and 18F-NaF before and after 
therapy. Treatment response by means of PET/CT was assessed according to the 
European Organization for Research and Treatment of Cancer (EORTC) 1999 
criteria. The evaluation of dPET/CT studies was based on qualitative evaluation, 
semi-quantitative (SUV) calculation, and quantitative analysis based on 2-tissue 
compartment modelling and a non-compartmental approach leading to the extraction 
of fractal dimension (FD).  Results: An analysis was possible in 29 patients: 3 with 
clinical complete response (CR) and 26 with non-CR (13 patients near complete 
response-nCR, 4 patients very good partial response-VGPR, 9 patients partial 
response-PR). After treatment, 18F-FDG PET/CT was negative in 14/29 patients and 
positive in 15/29 patients, showing a sensitivity of 57.5% and a specificity of 100%. 
According to the EORTC 1999 criteria, 18F-FDG PET/CT-based treatment response 
revealed CR in 14 patients (18F-FDG PET/CT CR), PR in 11 patients (18F-FDG 
PET/CT PR) and progressive disease in 4 patients (18F-FDG PET/CT PD). In terms of 
18F-NaF PET/CT, 4/29 pts (13.8%) had a negative baseline scan, thus failed to depict 
MM. Regarding the patients, for which a direct lesion-to-lesion comparison was 
feasible, 18F-NaF PET/CT depicted 56 of the 129 18F-FDG positive lesions (43%). 
Follow-up 18F-NaF PET/CT showed persistence of 81.5% of the baseline 18F-NaF 
positive MM lesions after treatment, despite the fact that 64.7% of them had turned to 
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 3 
18F-FDG negative. Treatment response according to 18F-NaF PET/CT revealed CR in 
1 patient (18F-NaF PET/CT CR), PR in 5 patients (18F-NaF PET/CT PR), SD in 12 
patients (18F-NaF PET/CT SD), and PD in 7 patients (18F-NaF PET/CT PD). Dynamic
 
18F-FDG and 18F-NaF PET/CT studies showed that SUVaverage, SUVmax, as well as the 
kinetic parameters K1, influx and FD from reference bone marrow and skeleton 
responded to therapy with a significant decrease (p<0.001). Conclusion: 18F-FDG 
PET/CT demonstrated a sensitivity of 57.7% and a specificity of 100% in treatment 
response evaluation of MM. Despite its limited sensitivity, the performance of 18F-
FDG PET/CT was satisfactory, given that 6/9 false negative patients in follow-up 
scans (66.7%) were clinically characterized as nCR, a disease stage with very low 
tumor mass. On the other hand, 18F-NaF PET/CT does not seem to add significantly 
to 18F-FDG PET/CT in treatment response evaluation of MM patients undergoing 
HDT and ASCT, at least shortly after therapy.   
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INTRODUCTION 
High-dose chemotherapy (HDT) with melphalan followed by autologous stem cell 
transplantation (ASCT) is the standard of care for multiple myeloma (MM) patients 
aged 65 years or younger1,2,3,4,5. In the last years the incorporation of novel agents 
(thalidomide, lenalidomide, bortezomib) into induction regiments and maintenance 
therapy of MM has improved the quality of treatment response, which in turn has led 
to extended progression free survival (PFS) and overall survival (OS) rates4,6,7. This 
previously unreported, prolonged survival of MM patients renders accurate 
assessment of response to therapy a necessity. Treatment response evaluation in MM 
is based on well-defined laboratory parameters and in case of a complete serological 
response the assessment of plasma cell percentage in bone marrow usually acquired 
from the iliac crest 8,9.  
18F-FDG PET/CT is a sensitive functional imaging modality. The updated 
International Myeloma Working Group (IMWG) criteria consider patients with focal 
skeletal lesions and increased uptake with underlying osteolytic destruction in one of 
the new imaging modalities as indicative of active myeloma10,11. Although its routine 
application in the follow-up of MM is not yet recommended, 18F-FDG PET/CT 
appears to be useful in the monitoring of MM and has been proposed to strengthen the 
evaluation of the quality of treatment response12,13,14,15,16. 
18F-NaF is a PET tracer used for skeletal imaging, which accumulates in both 
osteoblastic and osteolytic lesions, reflecting regional blood flow and bone 
remodeling17,18,19,20. 18F-NaF PET/CT is evolving as an important imaging method for 
the assessment of malignant bone diseases 21 , 22 , 23 . Despite being suggested as a 
potential valuable tool in the assessment of MM24,25,26,27,28, three recently published 
prospective studies have yielded rather discouraging results, regarding the 
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 5 
performance of 18F-NaF PET/CT in evaluation of myeloma bone disease29 , 30 , 31 . 
Nevertheless, the data regarding application of 18F-NaF PET/CT in MM are still 
considered to be limited. 
The aim of this prospective study was to assess the combined use of the radiotracers 
18F-FDG and 18F-NaF in treatment response evaluation of a group of MM patients 
undergoing HDT followed by ASCT by means of static (whole-body) and dynamic 
PET/CT (dPET/CT). 
 
 
 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 6 
MATERIALS AND METHODS 
Patients 
The evaluation included initially 34 patients confirmed to suffer from MM based on 
the criteria established by the IMWG, at the time point of patient recruitment, and 
scheduled for treatment with HDT followed by ASCT32. All patients had primary 
disease and had never received chemotherapy. Their mean age was 59.1 years (range 
38-73 years). Table 1 presents analytically the characteristics of the patients 
investigated. Patients with a negative baseline 18F-FDG PET/CT were excluded from 
the statistical analysis in order to avoid bias in the interpretation of the results (n=5 
patients).  Patient data on PFS and OS up to July 2016 (time of writing) are also 
presented. The analysis was conducted in accordance to the declaration of Helsinki 
with approval of the ethical committee of the University of Heidelberg and the federal 
agency of radiation protection. 
 
PET/CT data acquisition 
All patients underwent PET/CT scanning with 18F-FDG and 18F-NaF before and after 
therapy with HDT and ASCT. The mean time between baseline and follow-up study 
was 95 days (range 47-228 days) (Table 1). The double tracer study in each patient 
was completed in two consecutive days. For reasons of radiation protection the 
patients were intravenously administered with a maximum dosage of 250 MBq 18F-
FDG (range 85-246 MBq) on the first day and respectively a maximum dosage of 250 
MBq 18F-NaF (range 167-247 MBq) on the second day. Data acquisition consisted of 
two parts for each tracer: the dynamic part (dPET/CT studies of the lower lumbar 
spine and the pelvic skeleton) and the static part (whole body PET/CT). Details 
regarding data acquisition are described in a previous publication of our group29. 
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PET/CT data analysis 
Data analysis was based on: visual (qualitative) analysis, semi-quantitative evaluation 
based on SUV calculations, and quantitative analysis of the 18F-FDG and 18F-NaF 
PET/CT scans, performed before (baseline PET/CT) and after (follow-up PET/CT) 
treatment.  
Qualitative analysis was based on visual assessment of the PET/CT scans, according 
to criteria applied in previous studies from our group29, 33 . Briefly, bone 
marrow/skeletal foci presenting with significantly enhanced 18F-FDG uptake, for 
which another benign aetiology was excluded, were considered indicative for 
myeloma. Afterwards, the results of 18F-NaF PET/CT were correlated to those of 18F-
FDG PET/CT, which served as reference. The basic concept regarding 18F-NaF 
PET/CT evaluation was that only lesions that correlated with respective lesions on 
18F-FDG PET/CT were considered as MM-indicative29.  
Semi-quantitative evaluation was based on volumes of interest (VOIs) and on 
subsequent calculation of SUVs. VOIs were drawn with an isocontour mode (pseudo-
snake) and were placed over sites of MM involvement as well as over reference 
tissue34. Bone marrow (in the case of 18F-FDG) and skeleton (in the case of 18F-NaF) 
of the 5th lumber vertebra and os ilium if without focal tracer enhancement served as 
reference tissue.  
Quantitative evaluation of the dynamic 18F-FDG and 18F-NaF PET/CT data, derived 
from reference tissue of the pelvis, was performed using a dedicated software and 
based on a two-tissue compartment model, with methods already reported in literature 
and performed previously from our group29,35,36,37,38,39,40,41. The application of a two-
tissue compartment model leads to the extraction of the kinetic parameters K1, k2, k3 
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 8 
and k4 as well as influx (Ki) that describe specific molecular processes for each tracer. 
In case of 18F-FDG, K1 reflects the carrier-mediated transport of 
18F-FDG from plas-
ma to tissue while k2 reflects the transport of the radiopharmaceutical back from tissue 
to plasma, and k3 represents the phosphorylation rate while k4 the dephosphorylation 
rate of the glucose analogue. Influx (Ki) is derived from the equation = (K1 x k3)/(k 2 + 
k3). In case of 
18F-NaF, rate constants K1 and k2 describe the fluoride ions exchange 
with hydroxyl groups of hydroxyapatite crystal of the bone and the reverse, while k3 
and k4 represent the formation of fluoroapatite and the opposite
25. Influx (Ki) is relat-
ed to Ca2+ influx and bone apposition rate and, presumably, represents bone remodel-
ling rate42. 
In addition to performing compartment analysis, a non-compartment model based on 
the fractal dimension (FD) for the time-activity data was also applied. FD is a parame-
ter of heterogeneity based on the box counting procedure of chaos theory and was 
calculated for the time activity data in each individual voxel of a VOI. The values of 
FD vary from 0 to 2 showing the more deterministic or chaotic distribution of the 
tracer activity via time in a VOI43.  
Treatment response evaluation by laboratory and imaging 
Treatment response evaluation was performed according to the clinical gold standard, 
based on the European Bone Marrow Transplantation Criteria, introduced by Bladé et 
al8 and modified by the IMWG uniform response criteria for multiple myeloma9. 
These criteria served as reference standard in our study. 
Treatment response by means of 18F-FDG PET/CT was assessed according to the Eu-
ropean Organization for Research and Treatment of Cancer (EORTC) 1999 criteria 
leading to four groups of therapy response (complete response, 18F-FDG PET/CT CR; 
partial response, 18F-FDG PET/CT PR; stable disease, 18F-FDG PET/CT SD; progres-
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 9 
sive disease, 18F-FDG PET/CT PD) 44. Due to lack of defined treatment monitoring 
criteria based on 18F-NaF PET/CT, we also applied the EORTC 1999 criteria for this 
tracer. 
Moreover, quantitative data derived from dynamic PET/CT studies from the pelvis 
were also applied in treatment response evaluation. In particular, the kinetic 
parameters retrieved from application of two-tissue compartment modelling as well as 
FD in reference bone marrow or skeleton were compared before and after therapy. 
 
Statistical analysis 
Data were statistically evaluated using the STATA/SE 12.1 (StataCorp) software on 
an Intel Core (2 · 3.06 GHz, 4 GB RAM) running with Mac OS X 10.8.4 (Apple Inc., 
Cupertino, CA, USA). The statistical evaluation was performed using the descriptive 
statistics and Wilcoxon rank-sum test. Moreover, we calculated the sensitivity and 
specificity of 18F-FDG PET/CT for determination of remission status based on the 
clinical gold standard8,9. The results were considered significant for p less than 0.001 
(p<0.001).  
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RESULTS 
Treatment response evaluation based on the clinical gold standard 
Patient population characteristics, as well as the results of treatment response 
evaluation are reported in Table 1. All patients showed at least partial clinical 
response after completion of HDT and ASCT. 5 MM patients had a negative baseline 
18F-FDG PET/CT scan and were, therefore, excluded from the statistical analysis. 
These 5 patients were also MM-negative on 18F-NaF PET/CT. Regarding the 
remaining 29 patients, 3 of them demonstrated complete response (CR) and 26 
demonstrated non-CR. In particular, 13 patients showed near complete response 
(nCR), 4 patients very good partial response (VGPR), and 9 patients showed partial 
response (PR) according to the clinical evaluation criteria. 
18F-FDG PET/CT evaluations  
Baseline 18F-FDG PET/CT demonstrated 129 MM-indicative focal lesions in 22 
patients. The comparison between 18F-FDG PET and the underlying low-dose CT 
findings in these 22 patients revealed 86 circumscribed osteolytic lesions in CT that 
correlated with the 18F-FDG avid PET lesions (66.7%). In 5 patients the number of 
lesions was too large to be exactly calculated (more than 20 lesions). 2 patients 
demonstrated an intense diffuse pattern of bone marrow uptake without focal lesions. 
No baseline EMD was detected. After treatment, 18F-FDG PET/CT became negative 
in 14 patients, while it remained positive in 15 patients. In correlation with the clinical 
gold standard, 18F-FDG PET/CT after therapy was true positive in 15/26 patients with 
non-CR, and false negative in 11/26 patients with non-CR, resulting in a sensitivity of 
57.7%. On the other hand, 18F-FDG PET/CT was true negative in 3/3 patients with 
CR, resulting in a specificity of 100%. 18F-FDG PET/CT demonstrated no false 
positive results in the skeleton. Two patients demonstrated on follow-up 18F-FDG 
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PET/CT pelvic lymphadenopathy and liver lesions. However, after correlation with 
clinical data, these findings were attributed to inflammatory/post-therapeutic changes 
and fungus infection respectively. Treatment response evaluation according to the 
EORTC 1999 criteria revealed 14 patients with CR (18F-FDG PET/CT CR), 11 
patients with PR (18F-FDG PET/CT PR), and 4 patients with PD due to development 
of new bone marrow lesions (18F-FDG PET/CT PD) (Table 2) (Figures 1, 3).  
18F-NaF PET/CT evaluations 
Regarding 18F-NaF PET/CT evaluations, 4/29 (13.8%) patients failed to depict any 
MM lesions on the baseline PET/CT. In the remaining patients 108 lesions were 
demonstrated on baseline 18F-NaF PET/CT. Follow-up 18F-NaF PET/CT showed that 
88 of the 108 (81.5%) baseline MM-indicative lesions were still 18F-NaF positive 
after treatment. In terms of treatment response, 1 patient showed 18F-NaF PET/CT-
CR, 5 patients 18F-NaF PET/CT-PR, 12 patients 18F-NaF PET/CT-SD, and 7 patients 
18F-NaF PET/CT-PD (Table 2) (Figures 2, 4). 
Comparison between 18F-FDG PET/CT and 18F-NaF PET/CT findings 
In 5 patients with innumerable 18F-FDG positive lesions, 18F-NaF PET/CT revealed a 
more limited disease extent on baseline scan. The 2 patients, who demonstrated an 
intense diffuse pattern of bone marrow uptake on 18F-FDG PET/CT, were 18F-NaF 
negative. Regarding the 22 patients, for who a direct lesion-to-lesion comparison was 
feasible, 18F-NaF PET/CT depicted 56 of the 129 18F-FDG positive lesions (43%). 57 
of the 88 lesions (64.7%) that were still positive on follow-up 18F-NaF PET/CT had 
already turned to 18F-FDG negative, thus were falsely classified as MM-positive by 
the follow-up 18F-NaF PET/CT, according to the criteria applied in the study.  
Survival data 
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The data on PFS and OS up to July 2016 (time of writing) are presented in Table 1. 
The follow-up time ranged from 15 to 52 months. Only one patient had died. 12 
patients demonstrated progression, while 18 patients were progression-free. One 
patient was lost to follow-up. Due to lack of late follow-up data for all patients, we 
did not proceed to survival analysis in order to compare the survival rates between the 
different groups.  
Kinetic analysis data 
The results of dPET/CT evaluations from reference tissue before and after therapy are 
presented in Tables 3, 4. In terms of both 18F-FDG dPET/CT and 18F-NaF dPET/CT, 
the patients responded to therapy with a statistically significant decrease of the semi-
quantitative parameters SUVaverage and SUVmax, as well as of the quantitative 
parameters K1, influx (Ki) and FD (p<0.001 respectively). The changes in the 
respective TACs for both tracers are presented in Figures 5, 6. 
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DISCUSSION 
Assessment of treatment response in MM is based on certain, well-defined laboratory 
parameters8,9. Nevertheless, novel imaging modalities such as PET/CT are nowadays 
considered valuable tools in improving the definition of response to therapy especially 
in case of complete response where the percentage of plasma cells in the bone marrow 
is assessed only from a single location at the iliac crest. Several studies have 
highlighted the potency of 18F-FDG PET/CT in accurate response evaluation to 
therapy in MM16, 45 , 46 , 47  while the role of 18F-NaF PET/CT in the evaluation of 
myeloma lesions is still being investigated. In the present prospective study we 
assessed the combined use of 18F-FDG PET/CT and 18F-NaF PET/CT in treatment 
response evaluation of MM patients undergoing HDT with melphalan followed by 
ASCT.  
In patient-based analysis 18F-FDG PET/CT showed a sensitivity of 57.7%, a result 
similar to results previously reported by Derlin et al. who found sensitivities of 54.6% 
and 50.0% for correct determination of remission status after stem cell transplantation 
using also the same clinical criteria as gold standard14,47. A possible explanation for 
this relatively limited sensitivity is that MM cells have a rather low proliferation rate 
and some lesions might be too small to be depicted, given that 6 of the false negative 
patients (66.7%) were clinically characterized as nCR, a disease stage with very low 
tumour mass14, 48.  The phenomenon of achievement of clinical CR with persistence of 
18F-FDG PET/CT positivity after therapy in MM has been studied by Zamagni et al 
and Bartel et al. These groups have highlighted the fact that MM patients with 
conventionally defined CR but with persistence of 18F-FDG PET/CT positive lesions 
have a higher risk of progression than 18F-FDG PET/CT negative patients12,13. 
Moreover, the Zamagni                                                                                                   
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group has proven that the achievement of conventional CR and 18F-FDG PET/CT 
negativity ensured a significantly prolonged progression free survival (PFS) and an 
extended overall survival (OS) compared to the achievement of conventional CR but 
with persistence of 18F-FDG avidity after therapy16. The specificity of 18F-FDG 
PET/CT was 100% with 3/3 patients clinically characterized as CR being 18F-FDG 
negative. 18F-FDG PET/CT is considered a relatively specific imaging modality 
regarding MM response assessment, due to its ability to differentiate between active 
disease and fibrotic lesions15,46. As expected, a direct comparison of the treatment 
response assessed by the clinical gold standard and 18F-FDG PET/CT was not 
feasible.  
The performance of 18F-NaF PET/CT was rather limited. In patient-based analysis, 
baseline 18F-NaF PET/CT was negative in 13.8% of the 18F-FDG PET/CT positive 
MM patients. Moreover, baseline 18F-NaF PET/CT depicted only 43% of the 18F-FDG 
positive lesions, a result in accordance with a previous study of our group involving 
67 MM patients, in which 18F-NaF PET/CT detected only 39% of the MM lesions 
demonstrated on 18F-FDG PET/CT29. Regarding follow-up studies, 18F-NaF PET/CT 
showed persistence of the majority (81.5%) of the baseline 18F-NaF positive MM 
lesions after treatment, despite the fact that 64.7% of them had turned 18F-FDG 
negative as a response to HDT and ASCT. The reason for this discordance between 
18F-FDG and 18F-NaF PET/CT findings lies on the different molecular mechanisms of 
the two tracers. 18F-FDG represents a direct parameter of tumour metabolism. A 
decline in the tumour 18F-FDG uptake is expected to be seen with a loss of viable 
cancer cells, which is in the case in patients with partial or complete response49. On 
the other hand, 18F-NaF uptake mechanism corresponds to osteoblastic activity. The 
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accumulation of 18F-NaF in osteolytic lesions, as in case of MM, takes place in the 
accompanying, even minimal, reactive osteoblastic changes19.  
To date there is little information available about the role of 18F-NaF PET in treatment 
monitoring of systemic cancer therapy. Hillner et al. have recently assessed the impact 
of 18F-NaF PET results in a set of 2,217 oncological patients receiving systemic 
therapy. Their results showed a high impact of the modality in patients with 
progressive osseous metastatic disease, with a 40% change in treatment plan after 18F-
NaF PET21. The authors stressed, however, the non-tumor specific nature of the tracer 
as an indicator of reactive bone formation in response to various insults, and the 
limitation of being subject to the flare phenomenon associated with systemic therapy. 
The experience from 99mTc-MDP bone scintigraphy (BS), the analogue of 18F-NaF 
PET for conventional nuclear medicine, is much larger. Although the response to 
treatment is evident through a decrease in 99mTc-MDP uptake in BS, several studies 
have shown that an increased activity of the bone-seeking tracer in the area of a 
tumour lesion may persist for several months after therapy, partly in terms of the 
healing, osteoblastic, reactive process,50,51,52,53,54. Garcia et al. evaluated the combined 
use of 99mTc-MDP BS and 18F-FDG PET in treatment response assessment of bone 
metastases in 25 patients suffering from breast and lung cancer. According to their 
results, 5 patients with improvement on 18F-FDG PET scans demonstrated PD and/or 
SD on 99mTc-MDP BS. Clinical follow-up, serial tumor markers and radiological 
findings confirmed the 18F-FDG PET findings, leading to the conclusion that some of 
the BS results should be interpreted as representing a persistent bone reaction, not 
active metastatic disease55. This previous experience with bone matrix radiotracers 
was the reason that the sensitivity and specificity of 18F-NaF PET/CT were not 
assessed with regard to the clinical gold standard.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 16 
Apart from the conventional evaluation of whole-body PET/CT scans, we performed 
quantitative assessment of the dynamic PET/CT data derived from reference bone 
marrow (18F-FDG), and reference skeleton (18F-NaF) of the pelvis after application of 
two-tissue compartment modelling. The quantitative aspect is a major advantage of 
PET, which is neglected when using whole-body protocols and visual/qualitative 
evaluation as the only diagnostic tool. Only limited data exist on quantitative 
assessment of tracer kinetics in MM. Our group has recently shown that the 18F-FDG 
kinetic parameters K1, influx (Ki), as well as SUV from reference bone marrow of the 
os ilium, correlated significantly with bone marrow malignant plasma cell infiltration 
rate40. The herein presented results revealed that in the case of 18F-FDG, tracer uptake 
(reflected by SUVaverage and SUVmax), its transport capacity (K1), and its influx rate 
(Ki) responded to HDT and ASCT with a significant decrease. These findings are in 
agreement with previous findings from Dimitrakopoulou-Strauss et al., who studied a 
group of MM patients undergoing anthracycline-based chemotherapy with dynamic 
18F-FDG PET/CT prior to the onset of therapy and after the first cycle. The authors 
found a significant decrease (p<0.000) of SUV, FD, VB, and influx (Ki) for 
18F-FDG 
as derived from reference bone marrow of the os ilium, in response to treatment56. 
The herein presented results provide more evidence in the direction of establishment 
of 18F-FDG PET/CT as a tool for treatment response evaluation in MM; we proved 
that in a group of patients that clinically responded to therapy with at least PR, certain 
parameters involved in 18F-FDG metabolism also responded with a significant 
decrease of their values. Considering that the particular 18F-FDG parameters correlate 
with the bone marrow malignant plasma cell infiltration rate, an indicator of myeloma 
burden and one of the myeloma defining events10, our data stress the capacity of 18F-
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FDG dynamic PET/CT to demonstrate bone marrow changes in response to treatment 
in a molecular level. 
Interestingly, 18F-NaF-associated kinetic parameters demonstrated similar changes as 
18F-FDG in response to therapy. In particular, 18F-NaF uptake (SUVaverage and 
SUVmax), the rate of fluoride ions exchange with hydroxyl groups of hydroxyapatite 
crystal of the bone (K1), Ca
2+ influx, bone apposition rate and, presumably, bone 
remodelling rate (Ki) decreased significantly after HDT and ASCT. Myelomatous 
bone disease after ASCT is little understood57. The fact that bone marrow 
transplantation may affect the skeleton has been demonstrated by Gandhi et al. in an 
heterogeneous group of oncological patients, one of which suffered from MM. The 
authors showed that 3 months after ASCT there was a significant decline of bone 
mineral density in the femoral neck and a non-significant trend towards reduction in 
the lumbar spine58. Terpos et al. have shown that bone formation markers do not 
normalise until the eighth month post-ASCT, providing an indication that bone 
formation may delay in normalising59. Further, in one of the few published treatment 
monitoring studies by means of dynamic 18F-NaF PET, Installé et al. have 
demonstrated in 14 patients with Paget’s disease receiving bisphosphonates therapy 
that SUVmax, K1, and influx constant Ki decreased significantly as response to 
treatment60. To the best of our knowledge, these are the first data regarding bone 
turnover changes in MM patients receiving HDT and ASCT, evaluated by means of 
dynamic PET/CT. 
In addition to two-tissue compartment modelling for tracer kinetics assessment, we 
also applied a non-compartmental approach based on the box counting procedure of 
the chaos theory for the analysis of dPET data, resulting in another index 
representative of tissue heterogeneity, fractal dimension (FD)43. Fractal geometry has 
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found use in pathology for assessment of irregularities61. Our group has shown that 
FD of 18F-FDG correlates significantly with the degree of bone marrow malignant 
plasma cell infiltration rate40. In the present study we found that FD for both tracers 
decreased significantly, reflecting a decline of the heterogeneity of the concentration 
of both tracers over time in response to treatment, a result in accordance with the 
changes of compartment-derived kinetic parameters. 
This study has some limitations. Firstly, the number of patients enrolled was relatively 
small. Therefore, further studies with a larger study population are warranted to 
generalize the herein presented results. Secondly, most of the PET/CT positive 
findings were not histopathologically confirmed. However, this is usually not possible 
in the clinical setting. Another limitation is the confinement of the dynamic PET/CT 
studies only in the anatomic area of the pelvis, since whole-body dynamic studies 
cannot be performed. We used a two-bed position protocol for the dynamic PET 
acquisition, which allows the study of a relatively large field of view of 44 cm. 
Nevertheless, new PET/CT scanners allow dynamic studies over several bed positions 
by using a continuous bed movement, thus, facilitating the use of dynamic protocols 
and reducing the whole acquisition time. Finally, the lack of late follow-up data for all 
patients prevented us from proceeding to survival analysis between the different 
patient groups, which will be the topic of a future publication of our group.  
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CONCLUSION 
In the present study 18F-FDG PET/CT demonstrated a sensitivity of 57.7% and a 
specificity of 100% in treatment response evaluation of 29 MM patients undergoing 
HDT and ASCT, using the clinical response criteria as reference standard. Despite its 
limited sensitivity, the performance of 18F-FDG PET/CT was satisfactory, given that 
6/9 false negative patients in follow-up scans (66.7%) were clinically characterized as 
nCR, a disease stage with very low tumor mass. In contrary, 18F-NaF PET/CT did not 
aid significantly in treatment response evaluation of MM patients, at least in an early 
phase. Dynamic PET/CT studies demonstrated a decrease of SUVs and specific 
kinetic parameters in reference tissue for both 18F-FDG and 18F-NaF as response to 
treatment, reflecting changes in a molecular level before any morphological changes 
take place.  
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FIGURE LEGENDS 
Figure 1: A 70-years old stage III MM patient scheduled for HDT and ASCT, 
undergoing 18F-FDG PET/CT before and after therapy. Maximum intensity 
projection (MIP) 18F-FDG PET/CT before therapy (left) revealed a mixed 
pattern of 18F-FDG uptake with intense, diffuse uptake in the axial skeleton 
and multiple, focal bone marrow lesions. Follow-up 18F-FDG PET/CT MIP 
three months after ASCT (right) demonstrated a complete remission of both 
diffuse bone marrow uptake as well as focal myeloma-indicative lesions (18F-
FDG PET/CT-CR). 18F-FDG uptake in cervical, abdominal and inguinal lymph 
nodes in the follow-up scan was attributed to inflammatory reaction after 
therapy, thus considered benign. Response according to clinical criteria was 
CR and according to the 18F-FDG PET EORTC criteria also CR. 
Figure 2: Whole body 18F-NaF PET/CT MIP before and after therapy of the 
same patient as in figure 1. Baseline 18F-NaF PET/CT (left) demonstrated 
several 18F-NaF positive skeletal lesions, which partly corresponded to 
respective lesions on 18F-FDG PET/CT (Fig. 1) and were considered myeloma-
indicative, as well as several degenerative changes mostly in the spine. Follow-
up 18F-NaF PET/CT MIP after therapy (right) showed remission of some of the 
MM-indicative lesions but at the same time persistence of several of them (18F-
NaF PET/CT-PR). Response according to clinical criteria was CR and 
according to the 18F-NaF PET criteria applied in our study PR. 
Figure 3: A 68-years old stage III MM patient scheduled for HDT and ASCT 
undergoing 18F-FDG PET/CT before and after therapy. Transaxial 18F-FDG 
PET/CT in the cervical level before therapy (upper row) revealed an 18F-FDG 
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avid, MM-indicative lesion in the transverse process of the 4th cervical 
vertebrae. The patient underwent a follow-up 18F-FDG PET/CT 49 days after 
ASCT (lower row), which demonstrated complete metabolic remission of the 
MM lesion. According to the EORTC 1999 criteria, the patient was 
characterized as 18F-FDG PET/CT-CR. According to clinical criteria, the 
patient`s response was nCR. 
Figure 4: Transaxial 18F-NaF PET/CT before and after therapy of the same 
patient as in figure 3. Baseline 18F-NaF PET/CT (upper row) revealed also the 
18F-FDG avid, myeloma-indicative lesion in the transverse process of the 4th 
cervical vertebrae as 18F-NaF positive. In contrary to 18F-FDG PET/CT (Fig.3), 
the lesion demonstrated a persistence of the 18F-NaF accumulation in the 
follow-up 18F-NaF PET/CT (lower row) after HDT and ASCT (18F-NaF 
PET/CT-SD).  
Figure 5: Time activity curves (TACs) depicting 18F-FDG concentration 
during the 60 minutes of dynamic PET acquisition in reference bone marrow 
before (upper row) and after therapy with HDT and ASCT (lower row). The 
curves are derived from bone marrow of the os ilium that served as reference 
(blue curve with green dots) and from the common iliac artery (curve with 
gold dots). Small decrease in the radiotracer concentration in reference tissue 
VOIs after therapy. The corresponding kinetic parameters responded to therapy 
also with a decrease.  
Figure 6: Time activity curves (TACs) depicting 18F-NaF concentration  
during the 60 minutes of dynamic PET acquisition in reference skeleton before 
(upper row) and after therapy with HDT and ASCT (lower row). The curves 
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are derived from osseous tissue of the os ilium that served as reference (blue 
curve with green dots) and from the common iliac artery (curve with gold 
dots). Decrease in the radiotracer concentration in reference tissue VOIs after 
therapy. The corresponding kinetic parameters responded to therapy also with 
a decrease.  
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Table 1 Characteristics, treatment response and survival rates of the patients 
investigated in the study. 
 
Patient 
number 
Stadiu
m 
Age Gender Time 
between 
ASCT-
follow-up 
PET (days) 
Clinical response 18F-FDG 
PET/CT 
response 
18F-NaF 
PET/CT 
response 
Prog
ressi
on 
after 
ther
apy 
PFS 
(mont
hs) 
OS (months) 
1 1 66 F 78 PR PR Negative 
baseline scan 
Yes 39 44  
2 3 65 M 228 CR CR PR Yes 16 49 
3 3 57 M 117 nCR PR SD Yes 17 32 
4 3 70 M 97 CR CR PR Yes 30 43 
5 3 73 M 132 nCR PR SD No 37 37 
6 1 53 M 64 PR CR SD No 31 31 
7 3 46 F 81 nCR CR SD Yes 26 35 
8 3 53 F 83 VGPR PR  SD Lost 
to 
follo
w-up 
  
9 3 69 F 52 PR CR CR Yes 4 41 
10 3 49 M 120 nCR CR Negative 
baseline scan 
No 28 28 
11 3 43 M 93 nCR PD PD No 28 28 
12 3 60 M 67 nCR PR PD Yes 9 18 (dead) 
13 3 68 M 75 nCR PR PR Yes 25 25 
14 3 69 M 101 nCR CR SD No 28 28 
15 3 68 F 49 nCR CR SD No 24 24 
16 3 53 M 70 PR CR SD No 26 26 
17 3 62 F 145 nCR PD PD Yes 20 27 
18 3 70 M 51 VGPR PR PD No 33 33 
19 1 60 M 115 PR PR SD No 24 24 
20 3 59 F 47 VGPR PR SD No 23 23 
21 3 60 M 86 CR CR SD No 52 52 
22 1 63 F 106 nCR CR Negative 
baseline scan 
No 23 23 
23 3 59 F 120 PR CR SD Yes 18 24 
24 3 48 M 102 nCR CR PR No 18 18 
25 3 61 M 89 PR PR Negative 
baseline  scan 
No 20 20 
26 3 45 M 67 PR PD PD No 20 20 
27 3 71 M 125 PR CR PR Yes 18 19 
28 3 59 F 128 nCR PR PD Yes 7 19 
29 3 62 F 55 VGPR PD  PD No 15 15 
30 1 62 M 105 VGPR Negative 
baseline scan 
(excluded) 
Negative 
baseline scan 
   
31 3 69 F 136 VGPR Negative 
baseline scan 
(excluded) 
Negative 
baseline scan 
   
32 3 38 M 48 VGPR Negative 
baseline scan 
(excluded) 
Negative 
baseline scan 
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33 3 46 M 98 nCR Negative 
baseline scan 
(excluded) 
Negative 
baseline scan 
   
34 3 54 M 86 nCR Negative 
baseline scan 
(excluded) 
Negative 
baseline scan 
   
M, male; F, female; CR, complete response;  nCR, near complete response; VGPR, very good partial 
response; PR, partial response; SD, stable disease; PD, progressive disease. 
All patients were alive at the time of writing, with the exception of patient no 12. 
 
 
 
Table 2 Treatment response of the 29 MM patients according to clinical criteria, 18F-
FDG PET/CT criteria and 18F-NaF PET/CT criteria. 
Clinical response 18F-FDG PET/CT response 18F-NaF PET/CT response 
CR= 3 patients 
nCR= 13 patients 
VGPR= 4 patients 
PR= 9 patients 
CR= 14 patients 
PR= 11 patients 
PD= 4 patients 
CR= 1 patient 
PR= 5 patients 
SD= 12 patients 
PD= 7 patients 
CR, complete response;  nCR, near complete response; VGPR, very good partial response; PR, 
partial response; SD, stable disease; PD, progressive disease 
 
 
 
Table 3 Descriptive statistics of mean and median values prior and after HDT and 
ASCT for the 18F-FDG semi-quantitative and quantitative parameters in reference 
bone marrow. The values of parameters K1, k2, k3, k4 and influx are 1/min. SUVs and 
FD have no unit. 
Parameter Mean prior Median prior Mean after Median after 
SUVaverage* 2.2 1.9 1.6 1.3 
SUVmax* 3.9 3.3 2.5 2.0 
K1* 0.214 0.186 0.158 0.144 
k2* 0.710 0.693 0.570 0.571 
k3 0.054 0.050 0.050 0.045 
k4 0.025 0.020 0.028 0.020 
influx* 0.014 0.013 0.011 0.009 
FD* 1.146 1.138 1.086 1.065 
*significant probabilities (p<0.001) 
 
 
 
Table 4 Descriptive statistics of mean and median values prior and after HDT and 
ASCT for the 18F-NaF semi-quantitative and quantitative parameters in reference 
skeleton. The values of parameters K1, k2, k3, k4 and influx are 1/min. SUVs and FD 
have no unit. 
Parameter Mean prior Median prior Mean after Median after 
SUVaverage* 8.7 8.4 6.9 6.3 
SUVmax* 14.6 13.8 10.5 10.0 
K1* 0.200 0.177 0.143 0.116 
k2 0.413 0.421 0.329 0.272 
k3 0.279 0.249 0.250 0.229 
k4 0.015 0.013 0.013 0.012 
influx* 0.076 0.070 0.059 0.054 
FD* 1.382 1.390 1.340 1.342 
*significant probabilities (p<0.001) 
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